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ABSTRACT

46

Background: Higher intakes of flavonoids provide health benefits, however, the importance

47

of each flavonoid class and which population groups may receive the greatest protection from

48

higher flavonoid intake warrants further investigation.

49

Objective: To explore the associations of flavonoid and flavonoid-rich wholefood intakes

50

with all-cause mortality and the moderating effects of early mortality risk factors.

51

Design: The study included 2 349 participants of The Blue Mountains Eye Study, with a

52

mean±SD age at baseline of 64.7±9.2 years. We calculated flavonoid intake from baseline

53

food frequency questionnaires using US Department of Agriculture food composition

54

databases. Associations were examined using adjusted Cox proportional hazards models.

55

Results: After 14 years of follow-up, 677 participants died. There was a flavonoid threshold

56

effect with the greatest risk reduction seen between low and moderate intakes of total

57

flavonoids, flavonoid classes and flavonoid-rich foods. Amongst the whole cohort,

58

participants in the highest tertile of anthocyanidin intake had a significantly lower risk of all-

59

cause mortality [multivariable adjusted HR (95%CI): 0.76 (0.61, 0.94)] when compared to

60

those in the lowest tertile. Amongst participants with at least one early mortality risk factor

61

(smoking, high alcohol consumption, no regular exercise or obesity), risk of all-cause

62

mortality was lower in those in the highest intake tertile for total flavonoids [adjusted HR:

63

0.77 (0.59, 1.00)], flavan-3-ols [0.75 (0.58, 0.98)], anthocyanidins [0.70 (0.54, 0.92)], and

64

proanthocyanidins [0.69 (0.52, 0.92)], compared to those in the lowest tertile. No similar

65

associations were observed among those without any risk factors. Similarly, consumption of

66

apples, tea and the individual flavonoid compounds, quercetin and epicatechin, were

4

67

associated with a lower risk of all-cause mortality among participants with at least one risk

68

factor, but not amongst other participants.

69

Conclusion: Moderate to high intakes of flavonoids and certain flavonoid subclasses may

70

provide health benefits, particularly for individuals with at least one early mortality risk

71

factor.

72

Keywords: Flavonoids, flavonoid-rich foods, all-cause mortality, prospective cohort

73

study
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74

INTRODUCTION:

75

Despite improvements seen in the past 25 years, dietary risk factors are still a major

76

contributor to the burden of non-communicable diseases (NCDs) in Australia, with an

77

estimated 19.7% of all deaths in 2015 attributable to dietary habits [1]. In particular an

78

estimated 8.4% of NCD deaths were attributable to either a diet low in fruit or a diet low in

79

vegetables. Of all NCD deaths attributable to dietary risks, 80.5% were related to

80

cardiovascular disease (CVD).

81

Beneficial effects of a diet rich in fruits and vegetables have partly been attributed to

82

flavonoids, a class of polyphenolic compounds found in plant-based foods and beverages [2].

83

Six main flavonoid subclasses have been defined: flavonols, flavan-3ols (including

84

proanthocyanidins), flavones, flavanones, anthocyanidins and isoflavones. There are at least

85

300 different flavonoid compounds commonly consumed in the human diet. However, most

86

of our total flavonoid intake is derived from fewer than 30 flavonoid compounds. The

87

bioactivity of these compounds and their circulating metabolites differ [3], meaning it is

88

likely that not all flavonoids will have the same impact on health outcomes [4, 5]. Several

89

cohort studies have reported an inverse association between high flavonoid intakes and all-

90

cause mortality [6], CVD-related mortality, and coronary heart disease (CHD)-related

91

mortality [7]. These results are supported by short-term randomised controlled trials

92

demonstrating that flavonoids and flavonoid-rich foods and beverages positively influence

93

measures related to the development and progression of CVD [8-10]. Whilst such studies

94

support a protective effect of a flavonoid rich diet, none have yet examined whether or not

95

these effects are consistent amongst individuals with and without unhealthy lifestyle

96

behaviours, particularly smoking and excessive alcohol intake, both of which increase the

6

97

risk of mortality [1]. Thus, the potential for a moderating impact of such behaviours on the

98

beneficial effects of a flavonoid-rich diet is unknown.

99

Therefore, the primary aim of this study was to investigate the associations between intakes

100

of total flavonoids, flavonoid subclasses and major individual flavonoid compounds, as well

101

as flavonoid-rich wholefoods and beverages and all-cause mortality in a cohort of older

102

Australians. Secondary aims were to investigate associations with CVD- and CHD-related

103

mortality and to explore whether these associations are modified in the presence of risk

104

factors for early mortality.

105
106

SUBJECTS AND METHODS:

107

Study Population

108

This was a prospective cohort study, conducted using data from the Blue Mountains Eye

109

Study (BMES). Details of the BMES methods have been previously reported [11, 12].

110

Briefly, the BMES was the first large population-based assessment of visual impairment and

111

common eye diseases, conducted in a representative older Australian community. The study

112

recruited participants within a geographically defined area, in the Blue Mountains region of

113

New South Wales (postcodes 2780 and 2782). The study population was representative of the

114

Australian population demographically and for socio-economic status (SES), although they

115

were slightly older on average [12]. All permanent, non-institutionalised residents, aged 49-

116

97 years, identified in a door-to-door census, were invited to participate. Of the 4433 eligible

117

residents, 3654 (82.4%) participated in baseline examinations during 1992–1994. Starting in

118

1992, the population has been followed for up to 15 years. The study was approved by the

7

119

Western Sydney Area Human Research Ethics Committee and was conducted in adherence to

120

the tenets of the Declaration of Helsinki.

121

Participants who did not complete a food frequency questionnaire (FFQ) at baseline (n=756)

122

and those with implausible energy intakes [<2,092 kJ/day (<500kcal/day) and >14,644 kJ/day

123

(>3,500kcal/day)] (n=38) were excluded from the analysis. All participants with a history of

124

diabetes (n=160) or major CVD (acute myocardial infarction or stroke, n=351) at baseline

125

were excluded from the analysis (Figure 1). The participants provided their previous medical

126

history and current medications verified by their General Practitioner. These data were coded

127

using the International Classification of Primary Care-Plus method. This coding methodology

128

allows aggregation of different terms for similar pathologic entities as defined by the

129

International Classification of Disease (ICD-10) coding system. These data were used to

130

determine the presence of pre-existing diabetes, major CVD and/or stroke.

131

Dietary Assessment

132

Dietary data were collected using a 145-item self-administered semi-quantitative FFQ,

133

modified for the Australian diet and vernacular from an early FFQ by Willett et al. [13].

134

Respondents were asked to indicate their usual frequency of consuming food items during the

135

past year, using a nine-category frequency scale that ranged from never to four or more times

136

per day. Each food was presented on the FFQ with a standard portion size. An allowance for

137

seasonal variation of fruit and vegetables was made by weighting seasonal fruits and

138

vegetables. The FFQ has been tested for reproducibility and validity in a subsample of the

139

study population against weighed food records for nutrients and individual food items [14,

140

15].

141

Exposures
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142

Estimates of the flavonoid content of foods in the FFQ and beverage questionnaire were

143

derived from the US Department of Agriculture (USDA) Database for the Flavonoid Content

144

of Selected Foods [2], the USDA Database for the Isoflavone Content of Selected Foods [16]

145

and the USDA Database for the Proanthocyanidin Content of Selected Foods [17]. The

146

method of estimating the flavonoid content of foods was similar to that outlined by Mink et

147

al. [18]. For each food we estimated the intake of each individual flavonoid compound

148

present. The total intake of each class of flavonoids was then calculated by summing each

149

individual flavonoid compound within that flavonoid class. Total flavonoid intake was

150

calculated by summing each of the flavonoid classes. The flavan-3-ol content of foods was

151

considered to represent the average of total flavan-3-ol and proanthocyanidin monomer

152

contents. For foods where only the flavan-3-ol or proanthocyanidin monomer content was

153

available, the single value provided was used to represent the flavan-3-ol content. The

154

proanthocyanidin content of foods was calculated by summing the proanthocyanidin dimers,

155

trimers, 4–6mers, 7–10mers and polymers. Where multiple varieties of a food listed in the

156

FFQ were reported in the databases, the average flavonoid content of all similar varieties was

157

computed, consistent with the descriptors used in the FFQ output. Foods in the FFQ that were

158

not in the flavonoid databases were assumed to contain no flavonoids. Intakes of flavonoid

159

classes (in mg/d) were calculated by multiplying the estimated intake (g edible portion/d)

160

from the FFQ and beverage questionnaire, with the flavonoid class content (mg/g edible

161

portion) of each food item on the questionnaire. Estimations for some of the food items were

162

made using generic recipes found online.

163

Study outcomes

164

The primary outcome of this study was death from any cause. Cause of death data were

165

obtained from the Australian National Death Index (NDI). CVD mortality data were obtained

9

166

by matching cause of death codes for CHD and stroke (see below) to the codes recorded in

167

the NDI up until 31 December 2007 (i.e., 14 years of follow up). Those who were unable to

168

be matched to the NDI (5%) were excluded from the analysis. Causes of death in the NDI

169

were defined using the 9th revision of International Classification of Diseases Code (ICD-9)

170

and International Statistical Classification of Diseases, 10th revision (ICD-10), with the

171

following codes used for CHD: (ICD-9:410.0 to 410.9, 411.0 to 411.8, 412.0, 414.0 to 414.9

172

and ICD-10:I21.0 to I21.9, I22.0 to I22.9, I23.0 to I23.8, I24.0 to I24.9 and I25.0 to I25.9) or

173

stroke: (ICD-9:430.0 to 438.9 and ICD-10:I60.0 to I69.9). The data from the Australian NDI

174

have been validated, and reported to be highly sensitive and specific for CVD mortality

175

(92.5% and 89.6%, respectively) [38]. Over 14 years of follow-up there were 677 deaths with

176

548 recorded cases for CVD mortality in this cohort: 432 for CHD; 176 for stroke; and 60 for

177

both CHD and stroke as the co-primary causes of death.

178

Covariates

179

A physical examination and detailed questionnaires administered by trained interviewers [19,

180

20], were used to determine values for potential confounding variables including age, gender,

181

BMI, energy intake, physical activity, hypertension, hypercholesterolemia, smoking status

182

and SES. Weight was assessed using digital scales with participants wearing light clothes and

183

no shoes. Height was assessed using a stadiometer and BMI was calculated in kg/m2 at

184

baseline. Smoking status was determined using categories of never smoked, past smoker and

185

current smoker; participants were classified as a current smoker if they had stopped smoking

186

within the past 12 months [20]. Systolic and diastolic blood pressures were measured with the

187

participants seated for at least 5 minutes using a mercury sphygmomanometer. Participants

188

were deemed hypertensive if they were currently taking blood pressure-lowering medication

189

or had a systolic blood pressure ≥140 mmHg. If participants were taking cholesterol-lowering
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190

medication (statins) or had a total cholesterol ≥ 5.5 mmol/L, they were considered

191

hypercholesteremic. Total cholesterol levels were measured using fasting blood samples [21].

192

Use of blood pressure-lowering medication and cholesterol-lowering medication (statins)

193

were obtained from self-report and were verified by participants’ General Practitioners.

194

Participants were asked questions regarding walking exercise and the performance of

195

moderate or vigorous activities, as detailed elsewhere [22]. These data were categorized as

196

follows: 1) No physical activity; 2) No vigorous physical activity; 3) Vigorous physical

197

activity. We used home/unit owner (yes/no) as a proxy for SES. Potential dietary

198

confounding variables were calculated from the FFQ described above.

199

Statistical Analysis

200

An analytical protocol was developed prior to the commencement of analysis. Descriptive

201

data are presented as mean ± SD for normally distributed continuous variables, median (IQR)

202

for non-normally distributed continuous variables and as number (n) and percentage (%) for

203

categorical variables. The exposure variables were categorized by tertiles of intake [T1: 0-

204

33.3%; T2: 33.4-66.6%; T3: 66.7-100%]. Cox proportional hazard ratios (HR) and 95%

205

confidence intervals (CIs) for all-cause, CVD- and CHD-related mortality were computed

206

using tertiles of the exposure variables, where the lowest tertile (reflecting the lowest intakes)

207

was the referent category. Schoenfeld residuals were used to check the Cox proportional

208

hazards assumptions, with no evidence of violation for all outcomes. For all analyses, two

209

models were fit: 1) minimally-adjusted (age and gender) and 2) multivariable-adjusted (age,

210

gender, BMI, physical activity, alcohol intake, smoking status, SES, hypercholesterolemia

211

and hypertension). Given the aetiological focus of our research hypotheses, deaths from non-

212

CVD causes were censored rather than being treated as competing risks [23]. We tested for

213

nonlinear relationships using restricted cubic splines, with the exposure variables treated as
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214

continuous, excluding individuals with intakes more than 4 SD’s above the mean for each

215

exposure. The test of nonlinearity used analysis of variance to compare the model with only

216

the linear term to the model that included both the linear and the cubic spline terms. To

217

account for the possibility of reverse causality bias, we repeated all analyses after excluding

218

all events that occurred within the first 2 years. We tested for effect modification by gender

219

and age; interaction terms between flavonoid intakes and each of these factors were added to

220

the models and likelihood ratio chi-square tests were used to formally test for statistical

221

interaction. To test for potential modification by lifestyle behaviour pattern, we performed a

222

stratified analysis according to an a priori–defined risk of early mortality characterized by at

223

least one of the following risk factors: current smoking, alcohol intake >14 standard

224

drinks/week, BMI ≥ 30 kg/m2 or no physical activity. Hazard ratios were obtained from

225

models including the two main effects and the interaction term. As flavonoid intake is not

226

highly correlated with total energy intake, and we believe crude values to be more relevant

227

than energy-adjusted values, we did not include total energy intake as a covariate in model 1

228

or 2. Energy intake was however added to model 2 in a sensitivity analysis to assess its effect

229

on the primary outcome. In two additional sensitivity analyses, we separately added potential

230

dietary confounders (fibre, saturated fat, polyunsaturated fat, dietary cholesterol and vitamin

231

C) and a diet quality index to model 2. This diet quality index has been described elsewhere

232

[24]. Analyses were undertaken using IBM SPSS® Statistics version 21 (2012, Armonk, NY:

233

IBM Corp), STATA/IC 14.2 (StataCorp LLC) and R statistics (R Core Team (2016). URL

234

http://www.R-project.org/.). Statistical significance was set at p≤0.05 (two-tailed) for all tests.

235
236

RESULTS:

237

Baseline characteristics
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238

In this older Australian population (n=2 349), total flavonoid intake was normally distributed

239

with a mean of 861.9 mg/d and a SD of 467.5 mg/d. The mean age ± SD was 64.7 ± 9.2

240

years. The baseline characteristics of the study population overall, and stratified by total

241

flavonoid intake tertiles [T1 (8.8 - 599.9 mg/d); T2 (600 - 1105.9 mg/d); T3 (1106 - 1969

242

mg/d)], are shown in Table 1. Participants in the highest tertile of flavonoid intake were less

243

likely to be current or past smokers, were more likely to be hypertensive and had the lowest

244

intake of alcohol. Intakes of all dietary characteristics, including total energy, increased

245

across flavonoid tertiles.

246

Flavonoid intake

247

Mean intakes of each flavonoid subclass, the primary flavonoid compounds within each

248

subclass, and the top three dietary contributors to each subclass are presented in Table 2.

249

Pearson correlations between flavonoid subclasses varied from weak (r = -0.03 for

250

isoflavones and flavonols) to high (r = 0.97 for flavonols and total flavonoids). In this

251

population, flavan-3-ols were the greatest contributors to total flavonoid intake, with 96.9%

252

of flavan-3-ols in the diet coming from tea. Of those who drank at least one cup of tea per

253

week (82.0 %), flavan-3-ols accounted for approximately 77.2 % of total flavonoid intake.

254

The second highest contributors to total flavonoid intake were the proanthocyanidins, coming

255

primarily from apples and pears, followed by the flavanones, coming mainly from oranges,

256

orange juice and grapefruit and the flavonols, from tea. The flavonoid subclasses with the

257

lowest mean intakes were the anthocyanidins, coming predominantly from red wine and port,

258

the isoflavones, of which soybean intake contributed the most and lastly the flavones, found

259

mainly in oranges.

260

Associations between flavonoid intake and mortality
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261

During 28 608 person-years of follow-up, 677 out of 2 349 persons (28.8%) died from any

262

cause. Minimal- and multivariable-adjusted associations of total flavonoid and flavonoid

263

subclass intakes with all-cause mortality are shown in Table 3. There was a significant linear

264

trend for a lower risk of all-cause mortality across intake tertiles for the flavone, flavanone,

265

anthocyanidin and proanthocyanidins subclasses (p for trend <0.05), but only that for the

266

anthocyanidin subclass remained significant after multivariable adjustment (p for trend =

267

0.003). For total flavonoid, flavonol and flavan-3-ol intakes, those in the second tertile were

268

at the lowest risk of death from any cause. In the multivariable-adjusted models, the highest

269

tertile of anthocyanidin intake was associated with a significantly lower risk of all-cause

270

mortality (HR: 0.76; 95% CI: 0.61, 0.94), compared to the lowest tertile. The associations

271

between flavonoid intakes and death due to CVD and CHD are provided in Supplemental

272

Tables 1 and 2 under “Supplemental data” in the online issue. No significant associations

273

with any flavonoid subclasses were seen after adjustments were made for potential

274

confounders.

275

There was evidence that the relationship between flavonoid intake and all-cause mortality

276

was non-linear (Table 3) with the greatest hazard reductions seen in the second tertile for

277

many of the flavonoid subclasses. Therefore, restricted cubic spline curves for the

278

multivariable adjusted models were generated (Figure 2). The relationships between

279

flavonoid intake and all-cause mortality seen in Figure 2, support the interpretation of Table

280

3, which suggests possible threshold associations. For total flavonoid intake, and intakes of

281

flavonols, flavan-3-ols, flavanones and isoflavones, participants consuming less than the

282

median intake in tertile 1, had a trend of increased hazard of death from any cause.

283

Associations between flavonoid-rich food intake and all-cause mortality
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284

Associations between individual foods, contributing to greater than 20% of the intake of any

285

flavonoid subclass (Table 2), and all-cause mortality are presented in Table 4. In the

286

minimally-adjusted models, participants in the highest intake tertile had a significantly lower

287

hazard of mortality for tea, apple and pear, orange and red wine intakes when compared to

288

those in the lowest intake tertile. These relationships were attenuated in the fully-adjusted

289

models. For orange juice and grapefruit intakes, those in the second tertile appeared to be at

290

the lowest risk of dying from any cause.

291

In accordance with the flavonoid subclass results, multivariable-adjusted cubic splines

292

(Supplemental Figure 1) illustrate a threshold rather than a dose-response effect for

293

flavonoid-rich wholefoods.

294

Associations between individual flavonoid compounds and all-cause mortality

295

We only examined the relationship of individual flavonoid compounds with mean intakes

296

>10 mg/day from sources other than tea with all-cause mortality (Table 5). Several

297

individual flavonoid compounds are found almost exclusively in tea, and thus their

298

relationship with all-cause mortality will be a proxy for tea intake. In the minimally-adjusted

299

models, participants in the third tertile for epicatechin, catechin, malvidin and naringenin had

300

a significantly lower risk of all-cause mortality. For quercetin and hesperetin intakes, the

301

greatest risk reductions were seen for participants in the second tertile. These relationships

302

were weakened in the fully-adjusted models. Fully-adjusted spline curves for the relationship

303

between all-cause mortality and major flavonoid compounds are presented in Supplemental

304

Figure 2.

305

Effect modification

15

306

No effect modification by age or gender was observed for total flavonoids or any flavonoid

307

subclass (p-interaction >0.1). The associations of total flavonoid and flavonoid subclass

308

intakes with all-cause mortality, stratified by risk of early mortality, are shown in Table 6.

309

The protective effect of total flavonoids, flavonols, flavan-3-ols and proanthocyanidins was

310

limited to those participants with at least one risk factor (p for interaction <0.05). The risk of

311

all-cause mortality for flavone, flavanone and anthocyanidin intakes did not differ

312

significantly between the two groups. The associations of flavonoid-rich foods and intakes of

313

individual flavonoid compounds with all-cause mortality, stratified by risk of early mortality,

314

are shown in Supplementary Tables 3 and 4. The reduced risk associated with higher

315

intakes of apples, tea, quercetin and epicatechin was also limited to those participants in the

316

‘at risk’ group (p for interaction <0.05).

317

Sensitivity analyses

318

Including energy intake in model 2 did not change the estimates. Adjusting for other dietary

319

confounders such as fibre, saturated fat, polyunsaturated fat, dietary cholesterol and vitamin

320

C or a diet quality index did not change the outcomes materially. Excluding participants who

321

died within the first two years (n=59), to account for reverse causality bias, slightly

322

strengthened the relationship between total and individual flavonoid subclass intake and all-

323

cause mortality.

324
325

DISCUSSION

326

With almost 20% of NCD-related deaths and 42.3% of CVD deaths in Australia attributable

327

to dietary risk factors [1], identifying optimal dietary patterns for disease prevention is

328

crucial. In this prospective cohort study of 2 349 elderly Australians, we provide evidence of

16

329

a reduced risk of all-cause mortality with moderate to high intakes of flavonoids and

330

flavonoid-rich foods. Our results indicate that these effects plateau and that the greatest risk

331

reduction is seen when moving from a low to a moderate intake. We also demonstrate for the

332

first time that the inverse association between total flavonoid intake and all-cause mortality

333

was mostly apparent in participants with at least one risk factor for early mortality.

334

In this cohort, approximately 74% of total flavonoid intake was attributed to the flavan-3-ol

335

subclass and 15% came from the proanthocyanidin subclass, where tea and apples were the

336

major dietary contributors, respectively. Intakes of total flavonoids and of each flavonoid

337

subclass were comparable to those reported in another Australian prospective cohort study

338

examining the relationship between flavonoid intake and mortality [25]. In contrast, a

339

considerably lower total flavonoid intake has been reported in several other studies [6, 26, 27]

340

most likely explained by the lower intake of tea in these cohorts.

341

The findings in our study examining the relationship between total flavonoid intake and all-

342

cause mortality are consistent with other studies [18, 26-31]. Although there were apparent

343

risk reductions, they generally no longer remained significant after adjusting for potential

344

confounders. In a meta-analysis of eight studies, participants in the highest versus the lowest

345

category of total flavonoid intake had an 18% lower risk of all-cause mortality (RR: 0.82;

346

95% CI: 0.72–0.92) [7]. However, we and others have shown that the greatest risk reduction

347

is often seen in the moderate flavonoid intake groups [18, 27-29, 31]. Of these eight studies,

348

only one study demonstrated a significantly lower risk of all-cause mortality with high

349

compared to low flavonoid intake (HR: 0.38; 95% CI: 0.22–0.64) [6]. While there are several

350

key differences in study design, dietary assessment, and participant characteristics between

351

these prospective cohort studies, the age of the participants at baseline (80 ± 3 years) and the

352

inclusion of those with prevalent CVD in the study by Ivey et al., could explain why such a
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353

large risk reduction was observed as the population would have been at a very high risk of

354

mortality. Similar non-significant reductions in CVD-related mortality risk with moderate to

355

high flavonoid consumption have been demonstrated in the present study and others [18, 26].

356

Several studies have examined the relationship between individual flavonoid subclass intakes

357

and all-cause mortality [18, 26-29]. However, results are too inconsistent to suggest that one

358

flavonoid subclass may be more beneficial than another. In the present study, after adjusting

359

for potential confounders, the anthocyanidin subclass was associated with the lowest risk of

360

all-cause mortality while Ivey et al. showed that a high intake of the flavan-3-ol subclass was

361

associated with the lowest risk [28]. For individual flavonoid compounds we show that after

362

adjusting for potential confounders only high intakes of malvidin and moderate intakes of

363

epicatechin were significantly associated with a lower risk of mortality. However, there was a

364

trend for a lower risk with moderate intakes of quercetin and hesperetin and moderate to high

365

intakes of naringenin. To date, only one other study [30] has examined the relationship

366

between individual flavonoid compounds and all-cause mortality; Knekt et al., demonstrated

367

non-significant lower risks in all-cause mortality for quercetin, kaempferol, hesperetin and

368

naringenin.

369

To our knowledge, this is the first observational study to provide evidence that the protective

370

effects of flavonoids may be confined to populations with unhealthy lifestyle habits placing

371

them at an increased risk of early mortality. Cigarette smoking [32], obesity [33], high

372

alcohol consumption (>2 standard drinks per day) [34] and physical inactivity [35] have been

373

shown to have harmful effects on nitric oxide bioavailability, endothelial function, blood

374

pressure, inflammation, blood lipids, platelet function and thrombosis, while strong evidence

375

suggests that flavonoids can ameliorate these intermediate risk factors for CVD [36-40]. We

376

demonstrated that moderate total flavonoid, flavonol and flavan-3-ol intakes were associated

18

377

with a significantly lower risk of all-cause mortality in participants with at least one risk

378

factor while little or no benefit was seen in participants with none of these risk factors.

379

Consistent findings were observed with flavonoid-rich foods (apples and tea) and individual

380

flavonoid compounds (quercetin and epicatechin). This finding may partly explain why we

381

and others have shown only non-significant reductions in risk of all-cause mortality with

382

moderate to high flavonoid consumption. Analyzing this relationship in the entire study

383

population may have diluted the protective effect afforded by flavonoids to those at a higher

384

risk. That anthocyanidin intake was associated with a reduced risk in both the ‘at risk’ and

385

‘not at risk’ subgroups explains why this was the only flavonoid subclass associated with a

386

significantly lower risk of all-cause mortality in the whole study population. This finding

387

warrants further investigation in both observational studies and clinical trials. Additionally,

388

future clinical trials investigating the mechanisms behind the beneficial effects of flavonoids

389

should be conducted in cohorts at risk for CVD, where the potential for improvement might

390

be greater.

391

In the present study, our analyses suggest possible threshold levels for intakes of total

392

flavonoid, flavonoid subclass, individual flavonoid compounds and flavonoid-rich wholefoods,

393

rather than a dose response effect. Due to the observational nature of the study, we are not able

394

to infer causality or rule out residual or unmeasured confounding. Although adjusting for

395

dietary confounders such as fibre, saturated fat, polyunsaturated fat, dietary cholesterol and

396

vitamin C did not change the outcomes materially, the possibility of flavonoids being a marker

397

of other potentially protective unobserved dietary factors cannot be discounted. However,

398

benefits of flavonoids and flavonoid-rich foods were independent of overall diet quality as

399

associations were unchanged after adjustments for a healthy eating index. Additionally,

400

grouping all risk factors for early mortality together does not allow for the examination of

19

401

potentially different modifying effects. For this study we only used baseline dietary intake and

402

covariate data; it is possible that intakes may have changed over the 14 years of follow-up,

403

resulting in some non-differential misclassification of the exposures attenuating the power to

404

detect an association. A second FFQ was completed after 5 years of follow-up; out of 1480

405

participants who completed both FFQ’s, 64% stayed in the same tertile for total flavonoid

406

intake, 15.5% increased their total flavonoid intake and total 19.7% decreased their flavonoid

407

intake. It should also be noted that the estimation of flavonoid intake was based on a US

408

database, meaning that regional variation in the flavonoid content of foods could not be

409

accounted for in this study.

410

In this prospective cohort study, we demonstrate that a moderate to high intake of flavonoids

411

is protective against mortality in elderly Australians at an increased risk of early mortality. This

412

protective effect was not observed in participants without these risk factors. Results also

413

indicate threshold levels for which benefits are seen.

414
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Table 1. Baseline characteristics of study population
Total flavonoid intake tertiles

Total
population

1

2

3

n = 2349

n = 783

n = 783

n = 783

861.9 [421.4

286 [157.6 –

915 [851.6 –

1372.1 [1291.4

– 1291.4]

421.4]

981.6]

– 1462.9]

Age (years)

64.7 ± 9.2

63.2 ± 9.0

65.7 ± 9.6

65.1 ± 8.9

Gender (male), n (%)

971 (41.3)

339 (43.3)

327 (41.8)

305 (39.0)

Body mass index (kg/m2)

26.0 ± 4.4

26.4 ± 4.6

25.9 ± 4.4

25.8 ± 4.1

None

505 (22.0)

176 (23.2)

177 (23.0)

152 (19.9)

Not vigorous

1022 (44.6)

339 (44.7)

345 (44.8)

338 (44.3)

Vigorous

764 (33.4)

243 (32.1)

248 (32.2)

273 (35.8)

Never

1129 (49.4)

336 (44.6)

396 (41.5)

397 (52.1)

Quit

826 (36.2)

269 (35.7)

289 (37.6)

268 (35.2)

Current

329 (14.4)

148 (19.7)

84 (10.9)

97 (12.7)

Hypertensive, n (%)

1632 (69.7)

520 (66.7)

542 (69.3)

570 (73.1)

High cholesterol, n (%)

1578 (72.3)

509 (70.3)

541 (74.6)

528 (71.93)

SES (home/unit owner), n (%)

2079 (90.3)

664 (86.9)

720 (93.6)

695 (90.3)

2.1 ± 0.6

1.9 ± 0.6

2.1 ± 0.6

2.2 ± 0.6

Total flavonoid intake (mg/day),
median [IQR]
Sociodemographic characteristics

Physical activity, n (%)

Smoking status, n (%)

Dietary characteristics
Energy intake (kcals/day, ×1000)
Alcohol (drinks/week)

1.8 [0 – 10.5]

2.3 [0 – 10.5] 2.3 [0 – 10.5]

0.8 [0 – 8.3]

Dietary fibre (g/d)

27.3 ± 10.5

25.0 ± 9.7

28.0 ± 10.4

28.9 ± 11.0

Protein (g/d)

87.1 ± 27.1

81.7 ± 28.3

87.6 ± 25.9

91.8 ± 26.2

Carbohydrate (g/d)

233.1 ± 75.5

212.1 ± 74.6

235.9 ± 71.1

251.4 ± 75.7

Saturated fat (g/d)

29.6 ± 13.0

27.7 ± 13.1

29.5 ± 12.1

31.5 ± 13.5

Polyunsaturated fat (g/d)

12.5 ± 5.4

11.7 ± 5.4

12.6 ± 5.4

13.2 ± 5.2

Vitamin C (mg/d)*

182.5 ± 95.0

172.2 ± 87.7

186.1 ± 96.8

189.3 ± 99.4

Cholesterol (mg/d)

294.5 ±

283.5 ±

295.2 ±

136.4

139.4

130.4

Data expressed as mean ± SD unless otherwise stated.
*Vitamin C without dietary supplementation
SES, social economic status.

304.8 ± 138.6

Table 2. Flavonoid intake in study population
Top three dietary contributors
Flavonoid class

Respective compounds*

(percentage contribution to class

Intake (mg/d) #

intake)
Flavan-3-ols

Thearubigin;

Tea (96.9%); apples and pears

Epigallocatechin 3-gallate;

(1.0%); bananas (0.6%)

641.0 ± 426.1

Epigallocatechin;
Epicatechin 3-gallate;
Epicatechin; Catechin;
Theaflavin3-apgallate;
Theaflavin;
Theaflavin3apdigallate;
Gallocatechin
Proanthocyanidins

Monomers; dimers; trimers;

Apples and pears (42.8%); tea

4–6mers; 7–10mers;

(15.0%); plums (6.0%)

134.2 ± 90.8

polymers
Flavanones

Flavonols

Anthocyanidins

Hesperetin; Naringenin;

Orange (46.8%); orange juice

Eriodictyol

(26.1%); grapefruit (21.0%)

Quercetin; Kaempferol;

Tea (68.8%); apples and pears

Myricetin; Isorhamnetin:

(6.8%); beer (2.9%)

Malvidin; Cyanidin

Red wine (56.8%); port (18.7%);

Delphinidin; Petunidin;

apples and pears (8.9%)

34.5 ± 37.6

32.6 ± 15.7

17.1 ± 37.2

Peonidin; Pelargonidin
Isoflavones

Genistein; Daidzein;

Soybeans (24.8%); white bread

Glycitein

(14.9%); coffee (12.9%)

1.3 ± 1.6

Flavones

Luteolin; Apigenin

Orange (42.2%); meat and vegetable
soup (12.2%); green peas (10.3%)

*In descending order of mean intake
Intakes are presented as mean ± SD.

#

1.2 ± 0.8

Table 3. Hazard ratios of all-cause mortality by tertiles of flavonoid intake
Test for

Flavonoid intake tertiles

non-

1

2

3

No. deaths (%)

220 (28.1)

233 (29.8)

224 (31.2)

Intake (mg/d)*

286.1 (8.8 – 599.9)

915.2 (600 – 1105.9)

1372.1 (1106 – 1969)

Model 1

1.00

0.81 (0.67, 0.97)

0.90 (0.75, 1.09)

0.0059

Model 2

1.00

0.88 (0.72, 1.08)

0.98 (0.80, 1.20)

0.0343

217 (27.7)

229 (29.2)

231 (29.5)

13.4 (1.7 – 25.0)

34.4 (25.0 – 42.3)

49.4 (42.3 – 84.8)

Model 1

1.00

0.81 (0.67, 0.97)

0.93 (0.77, 1.12)

0.0896

Model 2

1.00

0.85 (0.69, 1.04)

0.98 (0.80, 1.20)

0.2418

No. deaths (%)

247 (31.5)

209 (26.7)

221 (28.2)

Intake (mg/d)*

0.44 (0.02 – 0.72)

1.02 (0.72 – 1.32)

1.77 (1.32 – 7.70)

Model 1

1.00

0.86 (0.71, 1.03)

0.75 (0.62, 0.90)

0.1199

Model 2

1.00

0.90 (0.74, 1.10)

0.83 (0.68, 1.02)

0.4691

No. deaths (%)

224 (28.6)

231 (29.5)

222 (28.4)

Intake (mg/d)*

49.1 (1.3 – 310.5)

729.7 (310.6 – 747.6)

1158.0 (747.9 – 1224.0)

Model 1

1.00

0.76 (0.63, 0.91)

0.86 (0.71, 1.03)

0.0270

Model 2

1.00

0.82 (0.67, 1.01)

0.92 (0.75, 1.13)

0.0725

linearity#

Total Flavonoids

HR (95% CI)

Flavonols
No. deaths
Intake (mg/d)*
HR (95% CI)

Flavones

HR (95% CI)

Flavan-3-ols

HR (95% CI)

Flavanones

No. deaths (%)

243 (31.0)

216 (27.6)

218 (27.8)

Intake (mg/d)*

4.3 (0.05 – 10.3)

24.8 (10.3 – 38.9)

64.3 (38.9 – 548.9)

Model 1

1.00

0.86 (0.72, 1.04)

0.79 (0.66, 0.94)

0.0192

Model 2

1.00

0.91 (0.75, 1.11)

0.91 (0.75, 1.16)

0.1243

No. deaths (%)

239 (30.7)

224 (28.6)

214 (27.3)

Intake (mg/d)*

0.60 (0.01 – 0.81)

0.99 (0.82 – 1.22)

1.61 (1.23 – 29.89)

Model 1

1.00

0.96 (0.80, 1.15)

0.98 (0.81, 1.18)

0.0630

Model 2

1.00

0.97 (0.79, 1.18)

0.99 (0.81, 1.21)

0.1482

No. deaths (%)

258 (33.0)

234 (29.9)

185 (23.6)

Intake (mg/d)*

2.1 (0.0 – 3.8)

5.6 (3.9 – 9.2)

21.3 (9.2 – 333.7)

Model 1

1.00

0.89 (0.74, 1.06)

0.66 (0.55, 0.80)

<0.0001

Model 2

1.00

1.04 (0.85, 1.26)

0.76 (0.61, 0.94)

0.0015

No. deaths (%)

250 (31.9)

227 (29.0)

200 (25.5)

Intake (mg/d)*

53.8 (0.2 – 85.9)

116.7 (86.0 – 155.4)

200.4 (155.5 – 747.8)

Model 1

1.00

0.88 (0.74, 1.05)

0.71 (0.59, 0.85)

0.0999

Model 2

1.00

1.01 (0.83, 1.23)

0.86 (0.70, 1.05)

0.4308

HR (95% CI)

Isoflavones

HR (95% CI)

Anthocyanidins

HR (95% CI)

Proanthocyanidins

HR (95% CI)

Hazard ratios (95% CI) for 14-year all-cause mortality analysed using multivariate Cox proportional hazard models.
Model 1 was adjusted for age and gender and model 2 was adjusted for age, gender, BMI, smoking status, physical
activity, alcohol intake, hypertension, hypercholesterolemia and social economic status.
*Median; range in parentheses (all such values). #Tests for nonlinearity used analysis of variance to compare the model
with only the linear term to the model that includes both the linear and the cubic spline terms.

Table 4. Hazard ratios of all-cause mortality by tertiles of flavonoid-rich foods
Food intake tertiles

Test for
non-

1

2

3

No. deaths (%)

129 (28.0)

110 (27.4)

438 (29.5)

Intake (ml/d)*

0 (0-35)

250 (108-250)

625 (625-1000)

Model 1

1.00

0.80 (0.62, 1.03)

0.77 (0.63, 0.94)

0.0276

Model 2

1.00

0.84 (0.63, 1.10)

0.84 (0.68, 1.05)

0.0770

No. deaths (%)

279 (32.4)

222 (28.0)

176 (25.3)

Intake (mg/d)*

10.5 (1 – 21.1)

64.7 (64.7 – 118.9)

150.5 (150.5 – 602)

Model 1

1.00

0.89 (0.74, 1.06)

0.70 (0.58, 0.85)

0.1800

Model 2

1.00

1.02 (0.84, 1.23)

0.83 (0.68, 1.03)

0.4240

No. deaths (%)

301 (50.8)

186 (26.2)

190 (28.0)

Intake (mg/d)*

2.5 (0 – 8.8)

53.8 (17.5 – 53.8)

125.0 (98.8 – 500)

Model 1

1.00

0.83 (0.69, 0.99)

0.75 (0.62, 0.90)

0.0416

Model 2

1.00

0.87 (0.72, 1.06)

0.83 (0.68, 1.02)

0.1188

No. deaths (%)

312 (31.9)

183 (22.3)

182 (33.1)

Intake (ml/d)*

2.5 (0 – 2.5)

17.5 (8.8 – 53.8)

125 (98.8 – 500)

Model 1

1.00

0.79 (0.66, 0.95)

1.00 (0.84, 1.21)

0.0198

Model 2

1.00

0.80 (0.65, 0.97)

1.05 (0.87, 1.28)

0.0251

linearity#

Tea

HR (95% CI)

Apples and pears

HR (95% CI)

Oranges

HR (95% CI)

Orange juice

HR (95% CI)

Red wine

No. deaths (%)

445 (31.5)

116 (27.0)

116 (22.8)

Intake (ml/d)*

0 (0 – 0)

2.4 (2.4 – 2.4)

16.8 (8.4 – 480)

Model 1

1.00

0.90 (0.73, 1.10)

0.77 (0.63, 0.95)

<0.0001

Model 2

1.00

0.91 (0.73, 1.14)

0.79 (0.62, 1.00)

0.0027

No. deaths (%)

434 (33.0)

114 (22.4)

129 (24.7)

Intake (mg/d)*

0 (0 – 0)

2.7 (2.7 – 2.7)

18.6 (9.3 – 532)

Model 1

1.00

0.69 (0.56, 0.85)

0.74 (0.60, 0.90)

0.0221

Model 2

1.00

0.79 (0.63, 0.99)

0.81 (0.66, 1.00)

0.1668

HR (95% CI)

Grapefruit

HR (95% CI)

Hazard ratios (95% CI) for 14-year all-cause mortality analysed using multivariate Cox proportional hazard models.
Model 1 was adjusted for age and gender and model 2 was adjusted for age, gender, BMI, smoking status, physical
activity, alcohol intake, hypertension, hypercholesterolemia and social economic status.
*Median; range in parentheses (all such values). #Tests for nonlinearity used analysis of variance to compare the model
with only the linear term to the model that includes both the linear and the cubic spline terms.

Table 5. Hazard ratios of all-cause mortality by tertiles of individual flavonoid compound intake
Flavonoid compound intake tertiles

Test for
non-

1

2

3

No. deaths (%)

224 (28.6)

227 (29.0)

226 (28.9)

Intake (mg/d)*

9.00 (1.33 – 15.83)

20.76 (15.84 – 25.16)

29.14 (25.17 – 54.81)

Model 1

1.00

0.82 (0.68, 0.98)

0.86 (0.72, 1.04)

0.1191

Model 2

1.00

0.85 (0.69, 1.04)

0.96 (0.78, 1.17)

0.2001

No. deaths (%)

239 (30.6)

228 (29.1)

210 (26.9)

Intake (mg/d)*

9.60 (0.59 – 16.10)

21.40 (16.11 – 25.21)

30.83 (25.22 – 66.42)

Model 1

1.00

0.80 (0.66, 0.96)

0.75 (0.62, 0.90)

0.0148

Model 2

1.00

0.80 (0.66, 0.98)

0.86 (0.70, 1.05)

0.0340

No. deaths (%)

221 (28.3)

245 (31.3)

211 (27.0)

Intake (mg/d)*

9.06 (0.20 – 13.46)

17.06 (13.47 – 20.22)

24.33 (20.23 – 57.22)

Model 1

1.00

0.96 (0.80, 1.15)

0.80 (0.67, 0.97)

0.0048

Model 2

1.00

1.00 (0.82, 1.23)

0.90 (0.73, 1.10)

0.0527

No. deaths (%)

254 (32.4)

231 (29.6)

192 (24.6)

Intake (mg/d)*

0.08 (0 – 0.44)

1.34 (0.45 – 2.49)

12.73 (251.04)

Model 1

1.00

0.96 (0.80, 1.14)

0.73 (0.60, 0.88)

0.0015

Model 2

1.00

0.98 (0.81, 1.19)

0.75 (0.60, 0.94)

0.0549

linearity#

Quercetin

HR (95% CI)

Epicatechin

HR (95% CI)

Catechin

HR (95% CI)

Malvidin

HR (95% CI)

Hesperitin

No. deaths (%)

249 (31.9)

207 (26.5)

221 (28.2)

Intake (mg/d)*

2.28 (0 – 5.66)

14.39 (5.67 – 25.60)

37.79 (25.63 – 214.91)

Model 1

1.00

0.79 (0.65, 0.95)

0.79 (0.66, 0.95)

0.0243

Model 2

1.00

0.84 (0.69, 1.03)

0.91 (0.75, 1.11)

0.1295

No. deaths (%)

247 (31.6)

217 (27.7)

213 (27.2)

Intake (mg/d)*

1.55 (0 – 3.37)

6.20 (3.38 – 10.39)

17.24 (10.40 – 333.11)

Model 1

1.00

0.82 (0.68, 0.98)

0.74 (0.62, 0.89)

0.0036

Model 2

1.00

0.89 (0.73, 1.08)

0.87 (0.71, 1.07)

0.1301

HR (95% CI)

Naringenin

HR (95% CI)

Hazard ratios (95% CI) for 14-year all-cause mortality analysed using multivariate Cox proportional hazard models.
Model 1 was adjusted for age and gender and model 2 was adjusted for age, gender, BMI, smoking status, physical
activity, alcohol intake, hypertension, hypercholesterolemia and social economic status.
*Median; range in parentheses (all such values). #Tests for nonlinearity used analysis of variance to compare the model
with only the linear term to the model that includes both the linear and the cubic spline terms.

Table 6. Hazard ratios of total mortality by tertiles of flavonoid intake stratified by risk of early mortality
Not ‘at risk’ group

‘At risk’ group

(n=1 209)

(n=1 140)

Flavonoid intake tertile

Flavonoid intake tertile

P-value for
interaction*

1

2

3

1

2

3

Model 1

1.00

1.02 (0.77, 1.36)

1.15 (0.87, 1.53)

1.00

0.69 (0.54, 0.88)

0.79 (0.61, 1.02)

0.013

Model 2

1.00

1.03 (0.76, 1.41)

1.20 (0.89, 1.63)

1.00

0.69 (0.53, 0.89)

0.77 (0.59, 1.00)

0.006

Model 1

1.00

1.07 (0.80, 1.43)

1.18 (0.89, 1.57)

1.00

0.64 (0.50, 0.82)

0.80 (0.63, 1.03)

0.015

Model 2

1.00

1.03 (0.76, 1.40)

1.20 (0.89, 1.62)

1.00

0.64 (0.49, 0.83)

0.77 (0.59, 1.01)

0.007

Model 1

1.00

0.86 (0.65, 1.14)

0.86 (0.66, 1.12)

1.00

0.91 (0.72, 1.16)

0.75 (0.58, 0.97)

0.238

Model 2

1.00

0.90 (0.67, 1.21)

0.82 (0.62, 1.08)

1.00

0.89 (0.69, 1.15)

0.79 (0.61, 1.03)

0.620

Model 1

1.00

1.00 (0.75, 1.33)

1.08 (0.81, 1.44)

1.00

0.62 (0.49, 0.80)

0.78 (0.61, 1.00)

0.028

Model 2

1.00

1.00 (0.74, 1.36)

1.10 (0.81, 1.49)

1.00

0.61 (0.47, 0.80)

0.75 (0.58, 0.98)

0.012

1.00

0.86 (0.64, 1.14)

0.87 (0.67, 1.13)

1.00

0.87 (0.68, 1.10)

0.78 (0.60, 1.00)

0.063

Total Flavonoids

Flavonols

Flavones

Flavan-3-ols

Flavanones
Model 1

Model 2

1.00

0.90 (0.67, 1.22)

0.88 (0.66, 1.17)

1.00

0.88 (0.68, 1.14)

0.81 (0.62, 1.07)

0.160

Model 1

1.00

0.91 (0.50, 1.65)

1.31 (0.75, 2.31)

1.00

0.97 (0.55, 1.70)

1.13 (0.65, 1.96)

0.247

Model 2

1.00

1.02 (0.54, 1.94)

1.31 (0.70, 2.45)

1.00

1.05 (0.56, 1.97)

1.17 (0.64, 2.17)

0.440

Model 1

1.00

0.96 (0.73, 1.25)

0.69 (0.52, 0.92)

1.00

0.91 (0.72, 1.16)

0.69 (0.53, 0.89)

0.191

Model 2

1.00

1.03 (0.79, 1.37)

0.71 (0.52, 0.96)

1.00

0.95 (0.73, 1.22)

0.70 (0.54, 0.92)

0.130

Model 1

1.00

0.95 (0.72, 1.27)

0.89 (0.67, 0.17)

1.00

0.90 (0.71, 1.14)

0.65 (0.49, 0.85)

0.021

Model 2

1.00

0.99 (0.73, 1.34)

0.91 (0.68, 1.22)

1.00

0.95 (0.74, 1.22)

0.69 (0.52, 0.92)

0.037

Isoflavones

Anthocyanidins

Proanthocyanidins

Hazard ratios (95% CI) for 14-year all-cause mortality analysed using multivariate Cox proportional hazard models.
Model 1 was adjusted for age and gender and model 2 was adjusted for age, gender, hypertension, hypercholesterolemia and social economic status.
*Likelihood ratio test was used to calculate the P-value for interaction by comparing the model with the product term between flavonoid intake (continuous) and risk
of early mortality (no/yes).

FIGURE LEGENDS
Figure 1. Consort flow diagram. AMI, acute myocardial infarction; CHD, coronary heart
disease; CVD, cardiovascular disease.
Figure 2. Cubic spline curves for the association between flavonoid intakes (mg/day) and allcause mortality among participants of the Blue Mountains Eye Study, adjusted for age,
gender, BMI, smoking status, physical activity, alcohol intake, hypertension,
hypercholesterolemia and social economic status. Individuals with intakes > mean+4 SD’s
were excluded for each subclass (n≤46).

Figure 1.

